Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.

Abstract

AIMS:

PTEN is a recently identified tumour suppressor inactivated in a wide variety of human cancers, including endometrial cancers. Mutation of the PTEN tumour suppressor gene has been reported in approximately 50-83% of endometrial adenocarcinoma. Despite this fact, study of the expression of PTEN protein in human tumours is limited. PTEN protein functions as a tumour suppressor by regulating the cell cycle and survival through signal transduction pathway. PTEN protein was considered to have a dual-specificity phosphatase activity, but it is now known that its principal physiological activity is mainly derived from its lipid phosphatase activity. The cyclin-dependent kinase inhibitor, p27, has been suggested as a downstream target of cell cycle arrest of PTEN in various in vitro studies. In this study, we evaluated the alteration of PTEN protein expression in endometrial carcinoma and assessed its relationship to the expression of p27, the presumed downstream target of PTEN.

METHODS AND RESULTS:

Immunohistochemical staining was performed on 66 cases of endometrial carcinoma including 61 endometrioid type and five serous type, using antibodies to PTEN and p27. Loss or decrease of PTEN expression was observed in 66% (40/61 cases) of uterine endometrioid carcinoma, whereas most uterine serous carcinoma (4/5 cases) showed intense PTEN expression. Four (30%) of 13 endometrial hyperplasia synchronous with endometrioid carcinoma demonstrated complete loss of PTEN expression. All endometrioid carcinoma synchronous with PTEN-negative endometrial hyperplasia showed loss of PTEN expression. Alteration of PTEN expression was not correlated with histological grade or stage. Decreased immunoreactivity of p27 was found in 48 cases (79%) of 61 endometrioid carcinoma, and 76% (36 cases) of them also showed loss or decrease of PTEN expression. Four of five uterine serous carcinoma revealed strong p27 immunoreactivity, all of which showed intense PTEN expression. A positive correlation between PTEN and p27 expression was statistically significant (Mantel-Haenszel chi2 test, P=0.001). Immunoreactivity of p27 was not related to histological grade and clinical stage.

CONCLUSION:

These results show that PTEN and p27 are differentially expressed in endometrioid type carcinoma compared with those of the serous type, and suggest that the cyclin-dependent kinase inhibitor, p27, is a downstream target of PTEN-dependent cell cycle arrest in endometrial carcinoma.

• Authors: H-J An, Y-H Lee, N-H Cho, J-Y Shim, J-Y Kim, C Lee, S-J Kim
• Journal: Histopathology (Histopathology) Vol. 41 Issue 5 Pg. 437-45 (Nov 2002) ISSN: 0309-0167 [Print] England
• PMID: 12405911 (Publication Type: Journal Article)

Chemical References

• Cell Cycle Proteins
• Neoplasm Proteins
• Tumor Suppressor Proteins
• Cyclin-Dependent Kinase Inhibitor p27
• Phosphoric Monoester Hydrolases
• PTEN Phosphohydrolase
• PTEN protein, human

Topics

• Carcinoma, Endometrioid (genetics, metabolism, pathology)
• Cell Cycle Proteins (genetics, metabolism)
• Cyclin-Dependent Kinase Inhibitor p27
• Cystadenocarcinoma, Serous (genetics, metabolism, pathology)
• Down-Regulation
• Endometrial Neoplasms (genetics, metabolism, pathology)
• Female
• Humans
• Immunoenzyme Techniques
• Neoplasm Proteins (metabolism)
• PTEN Phosphohydrolase
• Phosphoric Monoester Hydrolases (genetics, metabolism)
• Tumor Suppressor Proteins (genetics, metabolism)